Annexon names Mark Blumenkranz to board as Muneer Satter steps down
ANNX•Blumenkranz background
Blumenkranz is Stanford ophthalmology professor emeritus and co-director of its Ophthalmic Innovation Program; former chair of Stanford ophthalmology.
He co-founded Adverum Biotechnologies; led ophthalmic companies including Optimedica, Oculeve, and Kedalion Therapeutics through acquisitions.
Board appointment and departure
- Annexon named retinal surgeon and biotech entrepreneur Mark S. Blumenkranz to its board.
- Director Muneer Satter stepped down from the board.
